An indirect comparison between bosutinib, nilotinib and dasatinib in first-line chronic phase chronic myeloid leukemia

CONCLUSIONS: Overall, in these analyses bosutinib demonstrates equivalent efficacy to nilotinib and dasatinib in the treatment of patients with newly diagnosed CP-CML.PMID:33733983 | DOI:10.1080/03007995.2021.1896489

Source: Current Medical Research and Opinion - March 18, 2021 Category: Research Authors: Bogdan Muresan Carla Mamolo Joseph C Cappelleri Eric Leip Andrea Viqueira Bart Heeg Source Type: research